What is a monoclonal antibody infusion?
Monoclonal antibodies (mAB) can be administered to a patient via intravenous (IV) infusion in order to treat COVID-19. Monoclonal antibody treatment can only be provided under the order of a physician or licensed practitioner.
This treatment is authorized for patients meeting the criteria specified in the FDA’s Emergency Use Authorizations (EUAs) for these treatments, and, due to the extremely limited supply, patients must:
- Have tested positive for COVID-19 within the prior 7 days
- Be symptomatic
- Be at an increased risk of severe disease
- Not yet be sick enough to be hospitalized
Additional information can be found within the FDA EUA documents:
- Eli Lilly’s bamlanivimab treatment EUA
- Eli Lilly’s bamlanivimab treatment EUA fact sheet
- Regeneron Pharmaceutical’s casirivimab and imdevimab treatment EUA
- Regeneron Pharmaceutical’s casirivimab and imdevimab treatment EUA fact sheet
- Etesevimab EUA
Where is mAB available?
In Phase 1 of mAB distribution, this treatment became available through hospitals and health systems. In Phase 2, which is beginning now, mAB will be available for distribution through other non-hospital facilities such as long-term care centers; these facilities may provide mAB themselves if capable and willing, or can use an infusion partner.
Given that supply is extremely limited, it is critical for providers to administer mAB in accordance with the criteria and protocol set forth by the FDA and CDC to ensure maximum effectiveness of available infusions as described above and included in the EUA resources.
What are the next steps for LTCFs/SNFs/ALFs to order and access mAB?
Interested facilities can offer mAB internally if capable and willing, or can contact an infusion provider partner to coordinate a distribution plan. Each site can apply for an allocation of mAB for up to a 14-day period at a time and will be asked to assert that they will administer mAB per proper protocol.
- DPH will review all orders and allocate what is available on a pro-rata and demand-driven basis.
- Approved orders will be distributed typically within three to five business days.
- Once the orders are distributed, sites may work internally or with their infusion partners to schedule and administer mAB infusions to patients.
Additional Links and Resources
- Additional DPH ordering process details
- Monoclonal antibody infusion order form
- Monoclonal antibody clinically responsible attestation form
Get More COVID Data
For more data on Delaware COVID cases, testing and outcomes, including demographic breakdowns, go to My Healthy Community